About the Authors
- María Belén Jiménez-Díaz
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Sara Viera
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Javier Ibáñez
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Teresa Mulet
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Noemí Magán-Marchal
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Helen Garuti
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Vanessa Gómez
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Lorena Cortés-Gil
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Antonio Martínez
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Santiago Ferrer
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- María Teresa Fraile
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Félix Calderón
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Esther Fernández
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Leonard D. Shultz
-
Affiliation The Jackson Laboratory, Bar Harbor, Maine, United States of America
- Didier Leroy
-
Affiliation Drug Discovery and Technology, Medicines for Malaria Venture, Geneva, Switzerland
- David M. Wilson
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- José Francisco García-Bustos
-
Current address: Department of Microbiology, Monash University, Clayton, Australia
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Francisco Javier Gamo
-
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
- Iñigo Angulo-Barturen
-
* E-mail: inigo.x.angulo@gsk.com
Affiliation Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain
Competing Interests
María Belén Jiménez-Díaz, Francisco Javier Gamo, Sara Viera, Vanessa Gómez, Noemí Magán-Marchal, Helen Garuti, Lorena Cortés-Gil, Antonio Martínez, Santiago Ferrer, María Teresa Fraile, Félix Calderón, Esther Fernández, David M. Wilson, and Iñigo Angulo-Barturen are employees of GlaxoSmithKline. Javier Ibáñez, Teresa Mulet, and José Francisco García-Bustos were employees of GlaxoSmithKline during the conceptual and experimental phase of the work. Didier Leroy is an employee of the Medicines for Malaria Venture. María Belén Jiménez-Díaz, Sara Viera, Vanessa Gómez, Noemí Magán-Marchal, Helen Garuti, Lorena Cortés-Gil Javier Ibáñez, and Teresa Mulet were funded by the Medicines for Malaria Venture under a Miniportfolio Agreement with GlaxoSmithKline, Diseases of the Developing World, Tres Cantos Medicines Development Campus. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: IAB MBJD. Performed the experiments: SV VG NMM HG LCG MBJD. Analyzed the data: IAB MBJD SV. Contributed reagents/materials/analysis tools: MTF SF FC EF LDS. Wrote the paper: IAB. Reviewed and helped write the manuscript: DMW DL FJG FC MBJD SV. Initial analysis and implementation of strategy: IAB FJG JFGB. Approved the paper: MBJD FJG SV JI TM VG NMM HG LCG AM SF MTF FC EF LDS DL DMW JFGB IAB.